Sotera Health (SHC) delivered a clean third-quarter beat. Earnings of $0.27 per share topped the $0.24 consensus by 12.5% and grew 12.5% year over year, while revenue of $324.89 million beat expectations by 1.7% and rose 4.4%. The company's own Adjusted EPS was $0.29, up 12%, and GAAP diluted EPS rose to $0.20 from $0.17. The headline, however, is less important than what management said about the fourth quarter. After raising its constant-currency outlook in Q2, Sotera only reaffirmed it this time and flagged softening medical device demand, mostly in Europe. That is the central tension: the strongest segment growth of the year arrived alongside the first real demand caution of the year.

The quality of the beat is mostly solid. Sterigenics grew 8.2% in constant currency, up from 7.0% in Q2 and 6.1% in Q1. Pricing contributed 4.8%, and segment margin expanded 57 basis points to 56.1%. Nelson Labs swung from a 3.8% decline in Q1 to 9.2% growth, helped by a rebound in expert advisory services. Consolidated growth of only 4.4% reflects Nordion, whose revenue fell 11.5% in constant currency on expected Cobalt-60 harvest timing. Even so, Nordion's segment margin improved 71 basis points.

Adjusted EBITDA rose 3.9% to $170.7 million. The 52.5% margin was up nearly 100 basis points sequentially but slightly below last year's 52.7%. Below the operating line, net interest expense fell to $34.1 million from $39.1 million, so deleveraging did a meaningful share of the work in driving EPS growth faster than EBITDA.

The call is where the tone shifted. Management described European customer softness that began in mid-to-late Q3 as broad-based and characterized it as a "reduction in optimism." It guided Sterigenics to roughly 6% constant-currency growth in Q4 with no normal seasonal step-up. That stands in contrast to Q2, when management said it did not see a slowdown in demand and expected a meaningful second-half uptick. The North Carolina X-ray facility is also softening after a strong Q3. At Nelson Labs, segment margin fell 199 basis points to 32.1% on mix, and margin guidance moved down to about 30-32% from the low-to-mid 30s. Management also does not expect the advisory-heavy mix behind Q3's growth to persist.

The guidance math reinforces the caution. Reported ranges were trimmed to $1.233-$1.250 billion in revenue and $632-$641 million in Adjusted EBITDA, as the expected FX benefit shrank to 70 basis points from 100. Subtracting year-to-date results implies Q4 revenue of roughly $307-$324 million and Adjusted EBITDA of roughly $161-$170 million, both at or below Q3 levels. Full-year margin is now framed as about flat, a step back from the modest expansion implied earlier in the year.

There is still a credible offsetting story. Nelson's full-year growth outlook was raised to low-to-mid single digits and Nordion's to mid-single digits. Net leverage fell to 2.9x, inside the 2-3x target, and Moody's upgraded the credit rating in early October. Together, these open the door to buybacks, M&A or further debt paydown. Year-to-date operating cash flow rose to $228 million from $184 million despite a working-capital drag. Management reiterated its $500-$600 million 2025-27 free cash flow target, and with EO facility enhancements wrapping up in Q1 2027, it expects a meaningful capex step-down next year. Bears still have legitimate ammunition beyond demand. The quarter carried $11.7 million in excluded EO-related professional fees. California EO trials are scheduled for January and April 2027, and a Georgia appellate decision is due in spring 2027. Management offered no 2027 outlook, deferring it to February.

The market had already been cooling on the name. Shares closed at $17.74 ahead of the report, down 4.4% from the $18.55 open following the August release. That leaves them 10.3% below the $19.79 inter-earnings high set the day after that report and just 1.3% above the October low of $17.51. The stock remains about 4.3% above its 200-day moving average of $17.01. Investor sentiment stayed positive but softened modestly, slipping to 0.26 from 0.29. The internal trend readings are mixed, with momentum positive and AVWAP still negative.

The bottom line is that Sotera beat on accelerating Sterigenics and Nelson growth, with a strengthening balance sheet behind it, but the report traded Q2's upward momentum for a holding pattern. European med device softness, a flat Q4 at Sterigenics and a guide that implies sequential deceleration make February's 2027 outlook the real test. Until then, the credit upgrade and the coming capex step-down support the story more than near-term demand does.